作者
Elise Koch, Anders Kämpe, Maris Alver, Sindri Sigurðarson, Guðmundur Einarsson, Juulia Partanen, Robert L Smith, Piotr Jaholkowski, Heidi Taipale, Markku Lähteenvuo, Nils Eiel Steen, Olav B Smeland, Srdjan Djurovic, Espen Molden, FinnGen, Estonian Biobank Research Team, Engilbert Sigurdsson, Hreinn Stefánsson, Kári Stefánsson, Aarno Palotie, Lili Milani, Kevin S O’Connell, Ole A Andreassen
发表日期
2024/1/6
期刊
Neuropsychopharmacology
页码范围
1-7
出版商
Springer International Publishing
简介
Genomic prediction of antipsychotic dose and polypharmacy has been difficult, mainly due to limited access to large cohorts with genetic and drug prescription data. In this proof of principle study, we investigated if genetic liability for schizophrenia is associated with high dose requirements of antipsychotics and antipsychotic polypharmacy, using real-world registry and biobank data from five independent Nordic cohorts of a total of N = 21,572 individuals with psychotic disorders (schizophrenia, bipolar disorder, and other psychosis). Within regression models, a polygenic risk score (PRS) for schizophrenia was studied in relation to standardized antipsychotic dose as well as antipsychotic polypharmacy, defined based on longitudinal prescription registry data as well as health records and self-reported data. Meta-analyses across the five cohorts showed that PRS for schizophrenia was significantly positively …
学术搜索中的文章
E Koch, A Kämpe, M Alver, S Sigurðarson, G Einarsson… - Neuropsychopharmacology, 2024